BIOGEND THERAPEUTICS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.1 TWD | +0.13% |
|
-1.07% | -3.01% |
| Sales 2024 * | 150M 4.62M | Sales 2025 * | - | Capitalization | 4.57B 141M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 30.4 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.03% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.13% | ||
| 1 week | -1.07% | ||
| Current month | -2.11% | ||
| 1 month | -1.59% | ||
| 3 months | -2.37% | ||
| 6 months | +7.85% | ||
| Current year | -3.01% |
1 week
36.60
38.00
1 month
36.6038.70
Current year
36.6042.30
1 year
31.9549.65
3 years
19.1049.65
5 years
14.7464.20
10 years
14.7464.20
| Managers | Title | Age | Since |
|---|---|---|---|
Te Li Chen
CEO | Chief Executive Officer | 55 | 16-07-06 |
Tsang Cheng Lin
CEO | Chief Executive Officer | - | 18-04-29 |
Shu Wei Chao
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jung Chin Lin
BRD | Director/Board Member | 70 | 19-05-19 |
Hai Yi Ma
BRD | Director/Board Member | - | 18-05-19 |
Te Li Chen
CEO | Chief Executive Officer | 55 | 16-07-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 37.1 | +0.13% | 123,274 |
| 24-04-17 | 37.05 | +0.95% | 106,190 |
| 24-04-16 | 36.7 | -2.00% | 282,406 |
| 24-04-15 | 37.45 | -1.71% | 104,765 |
| 24-04-12 | 38.1 | +1.60% | 145,422 |
End-of-day quote Taipei Exchange, April 17, 2024
More quotes
BIOGEND THERAPEUTICS CO., LTD. is a medical equipment company mainly engaged in the development of biological aggregate. The Company is mainly engaged in the development and research of high-grade bone filling materials and knee cartilage repair related medical equipment. The Company's main products are BiG-001 which used for long bone biological aggregate, BiG-006 that used for lumbar interbody fusion biological bone, as well as BiG-009.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
37.1
TWD
Average target price
48
TWD
Spread / Average Target
+29.38%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.01% | 140M | |
| -1.82% | 41.36B | |
| +44.25% | 41.3B | |
| +2.56% | 39.61B | |
| -12.11% | 25.62B | |
| +3.09% | 24.09B | |
| -24.16% | 18.38B | |
| +22.12% | 11.85B | |
| -3.74% | 11.82B | |
| +7.75% | 11.07B |
- Stock Market
- Equities
- 6733 Stock
